Skip to main content

Incidence of Dyslipidemia Elevated During COVID-19 Pandemic

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 14, 2024.

via HealthDay

THURSDAY, Nov. 14, 2024 -- There was an increase in dyslipidemia incidence during the COVID-19 pandemic compared with the prepandemic period, according to a study published online Sept. 12 in the Journal of Clinical Investigation.

Valentina Trimarco, from Federico II University in Naples, Italy, and colleagues conducted a six-year longitudinal study to examine the broader effects of COVID-19 on the incidence of dyslipidemia in a real-world population of 228,266 individuals. Dyslipidemia incidence was compared during the COVID-19 pandemic (2020 to 2022) to the prepandemic period (2017 to 2019), with follow-up of at least 1,095 days (21,349,215 person-years).

The researchers found that the risk for developing dyslipidemia was increased during the COVID-19 period compared with the pre-COVID-19 period (odds ratio, 1.29), after adjustment for comorbidities in a multivariate analysis.

"The main finding of our study is the observation that the increased risk of dyslipidemia during the COVID-19 pandemic involved not only patients who had severe acute respiratory syndrome coronavirus 2 infection but the whole population," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

COVID-19 Tied to Higher Risk for Inflammatory Diseases of the Airways

THURSDAY, Aug. 28, 2025 -- People who have had COVID-19 have an increased risk for developing certain new-onset type 2 inflammatory diseases of the airways, while receipt of a...

COVID-19 Infection Linked to Accelerated Vascular Aging

MONDAY, Aug. 18, 2025 -- COVID-19 is associated with early vascular aging, as assessed by carotid-femoral pulse wave velocity (PWV), an established biomarker of large artery...

Larazotide May Speed Recovery in Children With Multisystem Inflammatory Syndrome

WEDNESDAY, Aug. 6, 2025 -- Treatment of multisystem inflammatory syndrome in children (MISC), a postacute sequela of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.